Cheryl Cohen


Since 2008, Ms. Cohen has served as president of CLC Consulting, a pharmaceutical and biotechnology consulting firm specializing in new product start-up and commercialization. 

Prior to CLC, Ms. Cohen served as chief commercial officer of Medivation, Inc., a publicly-traded bio-pharmaceutical company, from September 2011 until July 2014. From November 2007 to September 2008, she served as the vice president, strategic commercial group, of Health Care Systems, Inc., a Johnson & Johnson company, and from October 1998 to November 2007, she worked at Janssen Biotech, Inc. (formerly Centocor Biotech, Inc.), a Johnson & Johnson company, in a variety of senior sales roles including vice president, rheumatology franchise. 

In addition, Ms. Cohen served on the board of Aerpio Pharmaceuticals, Inc., a pharmaceutical company, since 2018 and also served on the board of Vital Therapies, Inc., a therapeutics company, from 2015 until 2019. 

Since 2015, Ms. Cohen has served on the board of Novus Therapeutics, Inc. (reverse merger of Tokai Pharmaceuticals, Inc.), a publicly-traded pharmaceutical company focused on the acquisition, development, and commercialization of ear, nose, and throat products and served on the board of Protein Sciences Corporation, a privately held bio-pharmaceutical company specializing in vaccine development from October 2014 to August 2017. She served on the board of Cytrx Corporation, a publicly traded bio-pharmaceutical company specializing in oncology, from June 2015 through October 2016. 

Ms. Cohen began her career at Solvay Pharmaceuticals in a variety of sales positions and received her B.A. from Saint Joseph College. 

Patrick Soon-Shiong,

Barry J. Simon, M.D.

John C. Thomas, Jr.

Fred Driscoll

Michael Blaszyk

Cheryl Cohen